OTCM
DSRNY
Market cap4.25bUSD
, Last price
USD
Name
DiaSorin SpA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
DiaSorin S.p.A. engages in research and development, manufacture, and distribution of immunodiagnostics and molecular diagnostics testing kits in Europe, North America, and internationally. It provides various immunodiagnostic in the areas, including infectious diseases, gastrointestinal diseases, hepatitis and retroviruses, endocrinology, metabolic disorders, tumor markers, and oncology under LIAISON XL and LIAISON XS name. The company also offers Simplexa, a congenital CMV direct kit, which detects cytomegalovirus DNA in saliva swab and urine specimens. In addition, it offers LIAISON PLEX Respiratory Flex Assay and the LIAISON PLEX Yeast Blood Culture Assay. Further, the company offers xMAP technology platform, including in vitro diagnostics. The company was founded in 1968 and is headquartered in Saluggia, Italy.
Related entities
Parent
FINDE S.P.A.
Subsidiaries (2)
DIASORIN INC.
DIASORIN ITALIA S.P.A.
Key people
Michele Denegri
Non-Executive Chairman of the Board · since 2022
Carlo Rosa
Chief Executive Officer, Executive Director, General Manager · since 2007
Giancarlo Boschetti
Non-Executive Vice Chairman of the Board · since 2022
Piergiorgio Pedron
Chief Financial Officer · since 2016
Chen Even
Executive Director, Chief Commercial Officer · since 2016
Stefano Ronchi
Senior Corporate Vice President - Human Resources · since 2007
Andre Ballester
Lead Independent Director · since 2022
Stefano Altara
Non-Executive Director · since 2014
Luca Melindo
Non-Executive Director · since 2019
Diego Pistone
Non-Executive Director · since 2022
Fiorella Altruda
Non-Executive Independent Director · since 2016
Non-Executive Independent Director · since 2007
Giovanna Parravicini
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2016
Roberta Somati
Non-Executive Independent Director · since 2013
Monica Tardivo
Non-Executive Independent Director · since 2016
Tullia Todros
Non-Executive Independent Director · since 2016
Headquarters & legal address
VIA CRESCENTINO, SNC
SALUGGIA, VC 13040
IT
SALUGGIA, VC 13040
IT
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||